Germany's Evotec subverts the traditional CRO model by cozying up to its development partners with risk-splitting deals, and the company's approach to R&D has attracted Debiopharm and Convergence Pharmaceuticals with programs in cancer and chronic pain.
Debiopharm, the Swiss diagnostics and drug conglomerate, committed $6 million in new financing to Immunexpress, a startup focused on developing a late-stage sepsis test.
Debiopharm, the Swiss diagnostics and drug conglomerate, committed $6 million in new financing to a startup focused on developing a late-stage sepsis test.
Swiss CRO Atheris Laboratories has signed a deal with Debiopharm to help develop a peptide cancer drug, optimizing leads for an innovative venom-derived treatment.
India's TCG Lifesciences has signed up to handle early phase work for Debiopharm's drug-resistant bacteria program, helping the Swiss drug developer as it chases a share of the antibiotics market.
The preclinical CRO Cenix BioScience has struck a deal to work with Germany's Debiopharm, putting its experts to work finding predictive biomarkers that can be used to advance the biotech's cancer drug candidates.
German CRO Cenix BioScience has agreed to handle preclinical work for Debiopharm's oncology pipeline, using its high-content assays to identify biomarkers.
Swiss drugmaker Debiopharma has teamed up with India's Shasun Pharmaceuticals, striking a deal with the CMO to manufacture Huperzine-A, a drug designed to improve cognitive performance in patients with Alzheimer's disease.
Debiopharm has signed on as the latest drug developer to attend Yale laboratories for some help with early-stage research work. Yale's "leadership in marrying chemistry and biology to identify and
Switzerland's Debiopharm will pay up to $25 million in R&D milestones to partner with Marina Biotech on the company's preclinical program for non-muscle invasive bladder cancer. Marina can look